Belgian clinical data show Allegro’s nanotech injection Hydrocelin delivers lasting knee osteoarthritis relief from a single shot.
Thirty people with bad knees got one injection. Six months later, most of them were still doing better. That’s the headline finding out of Liège, Belgium, where biomedical company Allegro just released the latest results from its ongoing Hydrocelin trial, and it’s the kind of number that tends to get buried under clinical language, so it’s worth just sitting with for a second: one shot, six months, still working [1].
Patients were scored on KOOS, a 100-point scale doctors use to track knee pain, daily function, and quality of life. Anything above an 8-to-10 point jump usually counts as clinically meaningful. Hydrocelin patients were already up a median 21.7 points at four weeks. By twelve weeks, that was 31.1. At six months, 35.7. All of it held up statistically against baseline.
What actually got investigators’ attention, though, wasn’t the size of those numbers, but the timing. Most patients felt real relief within the first week, not the slow build researchers are used to seeing with joint injections. Only one side effect showed up across the whole group: some soreness at the injection site, gone within a day.
Restoring shock absorption, not just masking pain
Most injectable treatments for knee osteoarthritis on the market do one of two things: lubricate the joint a bit, or numb the pain for a while. Hydrocelin is aiming at something underneath that. The cartilage breaks down, sure, but so does the joint’s ability to absorb shock in the first place, and that’s the piece Allegro says its cross-linked microparticles are built to replace. Once injected, they disperse through the synovial fluid and start behaving, mechanically, like the cushioning that used to be there.
“These successful clinical results with Hydrocelin in knee osteoarthritis patients represent an important milestone for Allegro, and give us confidence to progress as quickly as possible towards a future registrational study,” said Lucas Decuypere, CEO of Allegro. “The rapid onset of pain relief and the fact that the majority of patients remained pain-free through six months are particularly encouraging. Together, these findings support our belief that the key to improving osteoarthritis treatment lies in restoring the biomechanics of the joint.”
A second trial, moving faster than planned
Allegro also just finished dosing the last patient in a separate European feasibility study, 20 patients this time, spread across three centers in Belgium. That one’s mainly checking safety and tolerability at 13 weeks, with a full year of follow-up and efficacy tracked as a secondary measure. Recruitment for it wrapped in two months, fast for this kind of trial, and Allegro is reading that as a sign of how much doctors and patients want an alternative here. Topline data is expected sometime in the second half of 2026.
Dr Pieter-Jan Vandekerckhove, a knee surgeon at AZ Sint-Jan Hospital in Bruges and an investigator on that trial, put it plainly: “Osteoarthritis is a widespread and debilitating condition, yet today’s non-surgical treatments provide patients with only limited and temporary relief. The development of new technologies that aim to address the disease more fundamentally, as Allegro is doing, is long overdue. Prof Dr Frank Luyten, an advisor to Allegro, called the tolerability ‘very favorable’ and said the effect sizes so far look ‘promising in this patient population.’”
Why a knee matters more than it sounds like
Here’s the thing about knee pain specifically: it’s one of the most common reasons older adults quietly stop moving. Not all at once, either. They skip the walk, then the stairs, then eventually the gym they used to go to. And once that starts, a lot of what people worry about with aging tends to follow along behind it: muscle loss, weight gain, weaker bones. A knee that works isn’t really about the knee. It’s about whether someone keeps doing the things that protect them for the next twenty years.
Osteoarthritis already affects an estimated 650 million people globally, and Allegro cites projections putting that near one billion by 2050. If Hydrocelin’s results hold up at scale, and that’s still an if – this is early data from a small trial – it could give doctors a genuinely different tool, something that fixes the mechanics instead of just dulling the signal until the next appointment.
